Compounds > acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide
Page last updated: 2024-11-12

acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9960285
CHEMBL ID4297456
SCHEMBL ID2157375
SCHEMBL ID17262996
MeSH IDM0357737

Synonyms (27)

Synonym
SCHEMBL2157375
ac-phscn-nh2
atn 161 ,
acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide
l-aspartamide, 1-acetyl-l-prolyl-l-histidyl-l-seryl-l-cysteinyl-
unii-xw0h5le42k
xw0h5le42k ,
262438-43-7
atn-161
S8454
HY-13535
CS-3327
AKOS030210988
DTXSID60180877
SCHEMBL17262996
A919255
atn-161 free base
262438-43-7 (free base)
(s)-2-((r)-2-((s)-2-((s)-2-((s)-1-acetylpyrrolidine-2-carboxamido)-3-(1h-imidazol-5-yl)propanamido)-3-hydroxypropanamido)-3-mercaptopropanamido)succinamide
atn-161 (ac-phscn-nh2)
BS-16323
(s)-2-((r)-2-((s)-2-((s)-2-((s)-1-acetylpyrrolidine-2-carboxamido)-3-(1h-imidazol-4-yl)propanamido)-3-hydroxypropanamido)-3-mercaptopropanamido)succinamide
(2s)-2-(((2r)-2-(((2s)-2-(((2s)-2-(((2s)-1-acetylpyrrolidine-2-carbonyl)amino)-3-(1h-imidazol-4-yl)propanoyl)amino)-3-hydroxy-propanoyl)amino)-3-sulfanyl-propanoyl)amino)butanediamide
CCG-270186
D83668
CHEMBL4297456
AKOS040732486

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies in the Matrigel plug model of angiogenesis or a Lewis lung carcinoma model of tumor growth showed a U-shaped dose-response curve with 1 to 10 mg/kg given thrice a week, being the optimal dose range of ATN-161."( Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.
Beck, I; Doñate, F; Guan, X; Hensley, H; Kerbel, RS; Manuia, M; Mazar, AP; Parry, GC; Plunkett, ML; Shaked, Y; Shaw, DE; Tel-Tsur, Z, 2008)		0.35
"The presence of a U-shaped dose-response curve presents a significant challenge to identifying a biologically active dose of ATN-161."( Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.
Beck, I; Doñate, F; Guan, X; Hensley, H; Kerbel, RS; Manuia, M; Mazar, AP; Parry, GC; Plunkett, ML; Shaked, Y; Shaw, DE; Tel-Tsur, Z, 2008)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (41.18)29.6817
2010's4 (23.53)24.3611
2020's6 (35.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.56%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Apoplexy
[description not available]		02.4110
Anterior Choroidal Artery Infarction
[description not available]		02.4110
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.4110
Cerebral Infarction
The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).		02.4110
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		02.4110
2019 Novel Coronavirus Disease
[description not available]		03.6150
Acute Ischemic Stroke
[description not available]		02.6920
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.0140
Innate Inflammatory Response
[description not available]		02.2510
Ischemic Stroke
Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.		02.6920
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.2510
Cirrhosis
[description not available]		02.3110
Injury, Ischemia-Reperfusion
[description not available]		02.3110
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		02.3110
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		02.3110
Choroid Neovascularization
[description not available]		02.5120
Neovascularization, Optic Disc
[description not available]		02.1710
Retinal Neovascularization
Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.		02.1710
Disease Exacerbation
[description not available]		02.7630
Bone Cancer
[description not available]		02.4720
Breast Cancer
[description not available]		02.4720
Cancer of Lung
[description not available]		02.7430
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.4720
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.4720
Lung Neoplasms
Tumors or cancer of the LUNG.		02.7430
Cancer of Prostate
[description not available]		02.7130
Invasiveness, Neoplasm
[description not available]		02.4320
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.7130
Cancer of Liver
[description not available]		02.0110
Colorectal Cancer
[description not available]		02.0110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0110
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.0110
Benign Neoplasms
[description not available]		03.4111
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.4111
Adenocarcinoma, Basal Cell
[description not available]		02.0310
Metastase
[description not available]		02.4220
Angiogenesis, Pathologic
[description not available]		02.7330
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.0310
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.4220
Soft Tissue Neoplasms
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.		02.0310
Acute Disease
Disease having a short and relatively severe course.		02.0310
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.0310
Experimental Neoplasms
[description not available]		02.0410